CoChat

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers

Open access
George, Erin, Kim, Hyoung, Krepler, Clemens, Wenz, Brandon, Makvandi, Mehran, Tanyi, Janos L., Brown, Eric, Zhang, Rugang, Brafford, Patricia, Jean, Stephanie, Mach, Robert H., Lu, Yiling, Mills, Gordon B., Herlyn, Meenhard, Morgan, Mark, Zhang, Xiaochen, Soslow, Robert, Drapkin, Ronny, Johnson, Neil, Zheng, Ying, Cotsarelis, George, Nathanson, Katherine L., Simpkins, Fiona · 2017 · JCI Insight
Cited by 70

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Approximately 50% of high-grade serous ovarian cancers (HGSOCs) have defects in genes involved in homologous recombination (HR) (i.e., BRCA1 / 2 ). Preclinical models to optimize therapeutic strategies for HR-deficient (HRD) HGSOC are lacking. We developed a preclinical platform for HRD HGSOCs that includes primary tumor cultures, patient-derived xenografts (PDXs), and molecular imaging. Models were characterized by immunohistochemistry, targeted sequencing, and reverse-phase protein array analysis. We also tested PDX tumor response to PARP, CHK1, and ATR inhibitors. Fourteen orthotopic HGSOC PDX models with BRCA mutations ( BRCA MUT ) were established with a 93% success rate. The orthotopic PDX model emulates the natural progression of HGSOC, including development of a primary ovarian tumor and metastasis to abdominal viscera. PDX response to standard chemotherapy correlated to that demonstrated in the patient. Pathogenic mutations and HGSOC markers were preserved after multiple mouse passages, indicating retention of underlying molecular mechanisms of carcinogenesis. A BRCA2 MUT PDX with high p-CHK1 demonstrated a similar delay of tumor growth in response to PARP, CHK1, and ATR inhibitors. A poly (ADP-ribose) polymerase (PARP) inhibitor radiotracer correlated with PARP1 activity and showed response to PARP inhibition in the BRCA2 MUT PDX model. In summary, the orthotopic HGSOC PDX represents a robust and reliable model to optimize therapeutic strategies for BRCA MUT HGSOC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.89760

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 70

Metadata

Authors
George, E., Kim, H., Krepler, C., Wenz, B., Makvandi, M., Tanyi, J. L., Brown, E., Zhang, R., Brafford, P., Jean, S., Mach, R. H., Lu, Y., Mills, G. B., Herlyn, M., Morgan, M., Zhang, X., Soslow, R., Drapkin, R., Johnson, N., Zheng, Y., Cotsarelis, G., Nathanson, K. L., & Simpkins, F.
Venue
JCI Insight
Published
2017-01-12
Volume
2
Issue
1
Pages
e89760-e89760
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2578884323
Cited by
70
References
11
FWCI
3.77
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. https://app.cochat.ai/papers/10.1172/jci.insight.89760
The paper
George, E., Kim, H., Krepler, C., Wenz, B., Makvandi, M., Tanyi, J. L., Brown, E., Zhang, R., Brafford, P., Jean, S., Mach, R. H., Lu, Y., Mills, G. B., Herlyn, M., Morgan, M., Zhang, X., Soslow, R., Drapkin, R., Johnson, N., . . . Simpkins, F. (2017). A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight. https://doi.org/10.1172/jci.insight.89760

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.